Ces Urol 2023, 27(3):139-150 | DOI: 10.48095/cccu2023021

Prognostic factors of renal cell carcinoma

Marek Kašík, Michal Fedorko
Urologická klinika Fakultní nemocnice Brno a Lékařské fakulty Masarykovy univerzity, Brno

Kašík M, Fedorko M. Prognostic factors of renal cell carcinoma. Renal cell carcinoma is a very common tumour with slightly increasing both incidence and prevalence. Our role is in early detection of the disease and selecting the most optimal treatment option and surveillance after therapy. There are several prognostic factors and prognostic models that allow risk stratification. These tools provide information for treatment planning and patient counselling. The review summarizes the most commonly used prognostic factors of renal cell carcinoma with a focus on prognostic biomarkers.

Keywords: Biomarker, prognostic factor, prognostic model, renal cell carcinoma.

Received: May 24, 2022; Revised: June 21, 2023; Accepted: July 17, 2023; Prepublished online: July 17, 2023; Published: October 3, 2023 

Open full article

References

  1. Nádory ledvin - Epidemiologie a populační data ČR. Available from: https://www.uroweb.cz/index.php?pg=dg--nadory­‑ledvin--epidemiologie­‑ceska­‑republika--vyvoj­‑incidence­‑mortalita.Lucca I, de Martino M, Hofbauer SL, et al. Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinoma. World Journal of Urology. 2015; 33(12): 2045-52.
  2. Ballman KV. Biomarker: Predictive or Prognostic? Journal of Clinical Oncology. 2015; 33(33): 3968-+. Go to original source... Go to PubMed...
  3. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2021.
  4. Keegan KA, Schupp CW, Chamie K, et al. Histopathology of Surgically Treated Renal Cell Carcinoma: Survival Differences by Subtype and Stage. Journal of Urology. 2012; 188(2): 391-7. Go to original source... Go to PubMed...
  5. Chang YH, Chuang CK, Pang ST, et al. Prognostic value of TNM stage and tumor necrosis for renal cell carcinoma. Kaohsiung Journal of Medical Sciences. 2011; 27(2): 59-63. Go to original source... Go to PubMed...
  6. An JS, Packiam VT, Chennamadhavuni A, et al. Patient Characteristics and Survival Outcomes of Non­‑Metastatic, Non­‑Clear Cell Renal Cell Carcinoma. Frontiers in Oncology. 2022; 11. Go to original source... Go to PubMed...
  7. Wagener N, Edelmann D, Benner A, et al. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non­‑metastatic disease. Plos One. 2017; 12(9). Go to original source... Go to PubMed...
  8. Warren AY, Harrison D. WHO/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies. World Journal of Urology. 2018; 36(12): 191326. Go to original source... Go to PubMed...
  9. Lin TF, Lin WR, Chen M, et al. Compare fuhrman nuclear and chromophobe tumor grade on chromophobe RCC. Open Medicine. 2019; 14(1): 336-42. Go to original source... Go to PubMed...
  10. Ohashi R, Martignoni G, Hartmann A, et al. Multi­‑institutional re­‑evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two­‑tiered grading scheme. Virchows Archiv. 2020; 476(3): 409-18. Go to original source... Go to PubMed...
  11. de Peralta­‑Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma - A study of 101 cases. American Journal of Surgical Pathology. 2001; 25(3): 275-84. Go to original source... Go to PubMed...
  12. Lee SE, Byun SS, Oh JK, et al. Significance of macroscopic tumor necrosis as a prognostic indicator for renal cell carcinoma. Journal of Urology. 2006; 176(4): 1332-7. Go to original source... Go to PubMed...
  13. Vasudev NS, Wilson M, Stewart GD, et al. Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. Bmj Open. 2020; 10(5). Go to original source... Go to PubMed...
  14. O'Brian D, Prunty M, Hill A, Shoag J. The Role of C­‑Reactive Protein in Kidney, Bladder, and Prostate Cancers. Frontiers in Immunology. 2021; 12. Go to original source... Go to PubMed...
  15. Teishima J, Kobatake K, Shinmei S, et al. The effect of kinetics of C­‑reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. Urologic Oncology­‑Seminars and Original Investigations. 2017; 35(11). Go to original source... Go to PubMed...
  16. Jabs WJ, Busse M, Kruger S, et al. Expression of C­‑reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney International. 2005; 68(5): 2103-10. Go to original source... Go to PubMed...
  17. Tamura K, Matsushita Y, Watanabe H, et al. Feasibility of the ACL (albumin, C­‑reactive protein and lactate dehydrogenase) model as a novel prognostic tool in patients with metastatic renal cell carcinoma previously receiving first­­‑line targeted therapy. Urologic Oncology­‑Seminars and Original Investigations. 2020; 38(1). Go to original source... Go to PubMed...
  18. Tamura K, Ando R, Takahara K, et al. Development of novel ACN (albumin, C­‑reactive protein and neutrophil­‑to­‑lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first­­‑line molecular­‑targeted therapy. Urologic Oncology­‑Seminars and Original Investigations. 2021; 39(1). Go to original source... Go to PubMed...
  19. Yilmaz H, Yilmaz A, Demirag G. Prognostic significance of hemoglobin­‑to­‑red cell distribution width ratio in patients with metastatic renal cancer. Future Oncology. 2021; 17(29): 3853-64. Go to original source... Go to PubMed...
  20. Basmaci I, Celik S, Sefik E, et al. Evaluation of the Prognostic Value of Preoperative Neutrophil­‑tolymphocyte Ratio in Renal Cell Carcinoma. Journal of Urological Surgery. 2019; 6(3): 218- 24. Go to original source...
  21. Suppiah R, Shaheen PE, Elson P, et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer. 2006; 107(8): 1793-800. Go to original source... Go to PubMed...
  22. Zhang ND, Zhang HN, Zhu DQ, et al. Prognostic role of pretreatment lactate dehydrogenase in patients with metastatic renal cell carcinoma: a systematic review and meta­‑analysis. International Journal of Surgery. 2020; 79: 66-73. Go to original source... Go to PubMed...
  23. Shen J, Chen Z, Zhuang QF, et al. Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta­‑Analysis. Plos One. 2016; 11(11). Go to original source... Go to PubMed...
  24. Furniss D, Harnden P, Ali N, et al. Prognostic factors for renal cell carcinoma. Cancer Treatment Reviews. 2008; 34(5): 407-26. Go to original source... Go to PubMed...
  25. Kirkali Z, Lekili M. Renal cell carcinoma: new prognostic factors? Current Opinion in Urology. 2003; 13(6): 433-8. Go to original source... Go to PubMed...
  26. Rivet J, Mourah S, Murata H, et al. VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. Cancer. 2008; 112(2): 433-42. Go to original source... Go to PubMed...
  27. Bensalah K, Rioux­‑Leclercq N, Vincendeau S, et al. Is tumour expression of VEGF associated with venous invasion and survival in pT3 renal cell carcinoma? Progres En Urologie. 2007; 17(2): 189-93. Go to original source... Go to PubMed...
  28. Kluger HM, Siddiqui SF, Angeletti C, et al. Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Laboratory Investigation. 2008; 88(9): 962-72. Go to original source... Go to PubMed...
  29. Klatte T, Rossi SH, Stewart GD. Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World Journal of Urology. 2018; 36(12): 1943-52. Go to original source... Go to PubMed...
  30. Hodorova I, Solar P, Mihalik J, et al. Investigation of tumour supressor protein p53 in renal cell carcinoma patients. Biomedical Papers­‑Olomouc. 2014; 158(1): 44-9. Go to original source... Go to PubMed...
  31. Gudowska­‑Sawczuk M, Kudelski J, Mroczko B. The Role of Chemokine Receptor CXCR3 and Its Ligands in Renal Cell Carcinoma. International Journal of Molecular Sciences. 2020; 21(22). Go to original source... Go to PubMed...
  32. Bratu O, Mischianu D, Marcu D, et al. Renal tumor biomarkers (Review). Experimental and Therapeutic Medicine. 2021; 22(5). Go to original source... Go to PubMed...
  33. Tschirdewahn S, Panic A, Pullen L, et al. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma. International Journal of Cancer. 2019; 145(2): 531-9. Go to original source... Go to PubMed...
  34. Yang F, Song Y, Ge L, et al. Long non‑coding RNAs as prognostic biomarkers in papillary renal cell carcinoma. Oncology Letters. 2019. Go to original source...
  35. Felekkis K, Touvana E, Stefanou C, Deltas C. microRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia. 2010; 14(4): 236-40. Go to original source... Go to PubMed...
  36. Slaby O, Jancovicova J, Lakomy R, et al. Expression of miRNA-106 b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. Journal of Experimental & Clinical Cancer Research. 2010; 29. Go to original source... Go to PubMed...
  37. Griffiths­‑Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Research. 2008; 36: D154-D8. Go to original source... Go to PubMed...
  38. Esquela­‑Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nature Reviews Cancer. 2006; 6(4): 259-69. Go to original source... Go to PubMed...
  39. Wang F, Zhang HX, Xu NH, et al. A novel hypoxia­‑induced miR-147a regulates cell proliferation through a positive feedback loop of stabilizing HIF-1. Cancer Biology & Therapy. 2016; 17(8): 790-8. Go to original source... Go to PubMed...
  40. Iwamoto H, Kanda Y, Sejima T, et al. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. International Journal of Oncology. 2014; 44(1): 53-8. Go to original source... Go to PubMed...
  41. Iwamoto H, Osaki M, Honda M, et al. miR-210 as a Biomarker in Renal Carcinoma. Biomarkers in Kidney Disease. 2016; 1-2: 895-910. Go to original source...
  42. Lu J, Wei JH, Feng ZH, et al. miR-106 b-5p promotes renal cell carcinoma aggressiveness and stem­‑cell­­‑like phenotype by activating Wnt/beta­‑catenin signalling. Oncotarget. 2017; 8(13): 21461-71. Go to original source... Go to PubMed...
  43. Li YF, Chen DQ, Su ZM, et al. MicroRNA-106 b functions as an oncogene in renal cell carcinoma by affecting cell proliferation, migration and apoptosis. Molecular Medicine Reports. 2016; 13(2): 1420-6. Go to original source... Go to PubMed...
  44. Papadopoulos EI, Petraki C, Gregorakis A, et al. Clinical evaluation of microRNA-145 expression in renal cell carcinoma: a promising molecular marker for discriminating and staging the clear cell histological subtype. Biological Chemistry. 2016; 397(6): 529-39. Go to original source... Go to PubMed...
  45. Xu B, Wang C, Wang YL, et al. miR-143 inhibits renal cell carcinoma cells metastatic potential by suppressing ABL2. Kaohsiung Journal of Medical Sciences. 2020; 36(8): 592-8. Go to original source... Go to PubMed...
  46. Seles M, Hutterer G, Kiesslich T, et al. Current Insights into Long Non­‑Coding RNAs in Renal Cell Carcinoma. International Journal of Molecular Sciences. 2016; 17(4): 573. Go to original source... Go to PubMed...
  47. Wang W, Song J, Zhang W, et al. Identification of Long Non­‑Coding RNA Signatures for Specific Disease­‑Free Prognosis in Clear Cell Renal Carcinoma. IEEE Access. 2019; 7: 99290-8. Go to original source...
  48. Qu L, Wang ZL, Chen Q, et al. Prognostic Value of a Long Non­‑coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. European Urology. 2018; 74(6): 756-63. Go to original source... Go to PubMed...
  49. Guan Y, Xu F, Tian J, et al. The prognostic value of circulating tumour cells (CTCs) and CTC white blood cell clusters in patients with renal cell carcinoma. BMC Cancer. 2021; 21(1). Go to original source... Go to PubMed...
  50. Broncy L, Paterlini­‑Bréchot P. Circulating Tumor Cells for the Management of Renal Cell Carcinoma. Diagnostics. 2018; 8(3): 63. Go to original source... Go to PubMed...

Return to the content



Web časopisu Česká urologie je určen pouze pro lékaře a odborníky
z oblasti medicíny nebo farmacie.



Beru na vědomí, že informace zveřejněné na těchto stránkách
nejsou určeny pro laickou veřejnost.


Odejít Vstoupit